New bicyclic cannabinoid receptor-1 (CB1-R) antagonists.

[1]  A. Rissanen,et al.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study , 2005, The Lancet.

[2]  L. Petrocellis,et al.  The endocannabinoid system: a general view and latest additions , 2004, British journal of pharmacology.

[3]  J. Harrold,et al.  The cannabinoid system: a role in both the homeostatic and hedonic control of eating? , 2003, British Journal of Nutrition.

[4]  A. Horti,et al.  Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity. , 2003, Journal of medicinal chemistry.

[5]  J. Lange,et al.  Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists. , 2002, Chemical & pharmaceutical bulletin.

[6]  R. Nicoll,et al.  Endocannabinoid Signaling in the Brain , 2002, Science.

[7]  R. Pertwee,et al.  Pharmacology of cannabinoid receptor ligands. , 1999, Current medicinal chemistry.

[8]  P. Soubrié,et al.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.

[9]  P. Smith,et al.  The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. , 1994, The Journal of pharmacology and experimental therapeutics.

[10]  A. Howlett,et al.  Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.

[11]  T. P. Fondy,et al.  3-Fluoro-1-hydroxypropan-2-one (fluorohydroxyacetone) and some esters. Syntheses and effects in BDF mice. , 1977, Journal of medicinal chemistry.